Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders
13 Noviembre 2019 - 7:15AM
Business Wire
Vedanta Biosciences, a clinical-stage biopharmaceutical company
developing a new category of therapies for immune-mediated diseases
based on defined bacterial consortia, today announced that Silvia
Caballero, Ph.D., who leads Vedanta’s program on
multidrug-resistant organisms (MDRO), has been named to the TIME
100 NEXT list. The list honors individuals who are shaping the
future of their fields and defining the next generation of
leadership.
“Silvia is a rising star in the microbiome field and exemplifies
the spirit of this award. She seized onto the crucial public health
challenge of multidrug resistance as a doctoral student and
contributed scientific insights that have shaped our understanding
of the role of intestinal microbiota in resisting colonization by
gut pathogens,” said Bernat Olle, Ph.D., co-founder and chief
executive officer of Vedanta Biosciences. “She then continued to
drive forward research in the field by leading a discovery team at
Vedanta towards the identification of a drug candidate that could
potentially prevent MDRO infections, which could have enormous
potential to benefit patients around the world. We’re so proud that
Silvia has been recognized with this honor.”
Dr. Caballero leads Vedanta’s MDRO decolonization program, which
focuses on designing bacterial consortia to prevent infections with
MDROs and other gut pathogens by eliminating them from the
intestine, which is frequently colonized prior to infection. MDROs
are responsible for hundreds of thousands of infections in
high-risk patients in the United States and Europe each year.
Vedanta’s preclinical human microbiome-derived discovery program
represents a novel strategy that could potentially benefit patients
at high risk for infection as well as potentially aid in reducing
the use of antibiotics and the spread of antibiotic resistance.
Dr. Caballero earned her undergraduate degree in biological
sciences from Hunter College and doctorate degree from Weill
Cornell Medical College in microbiology and immunology, where she
developed microbiome-based tools to identify gut bacteria
responsible for fighting off MDROs. In 2018, Dr. Caballero was
named to the MIT Technology Review Innovators Under 35 Latin
America list. In 2019, she was named to MIT Technology Review’s
Global Innovators Under 35 list.
About Vedanta Biosciences Vedanta Biosciences is a
clinical-stage microbiome leader developing a new category of
therapies for immune-mediated diseases based on rationally-defined
consortia of human microbiome-derived non-pathogenic bacteria.
Vedanta’s proprietary capabilities include what is believed to be
the largest collection of human-gut associated bacteria, assays and
bioinformatics techniques for consortia design and optimization,
vast datasets from human interventional studies and facilities for
cGMP-compliant manufacturing of rationally-defined bacterial
consortia in powder form.
Vedanta Biosciences' pioneering work, in collaboration with its
scientific co-founders, has led to the identification of human
commensal bacteria that induce a range of immune responses –
including induction of regulatory T cells, CD8+ T cells, and Th17
cells, among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature (2013,
2019), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of investigational live biotherapeutic products
(LBPs) in infectious disease, autoimmune disease, allergy, and
immuno-oncology. This pipeline includes three clinical-stage
product candidates currently being evaluated for the treatment of
recurrent C. difficile infection and inflammatory bowel disease (in
collaboration with Janssen Biotech, Inc.), and food allergy, as
well as a fourth product candidate expected to enter the clinic in
2019 in patients with advanced or metastatic cancers (in
combination with Bristol-Myers Squibb’s checkpoint inhibitor
OPDIVO®).
Vedanta’s IP portfolio contains over 30 issued patents with
coverage through at least 2031. Vedanta Biosciences was founded by
PureTech Health (LSE: PRTC). Its scientific co-founders are
world-renowned experts in immunology and microbiology who have
pioneered the fields of innate immunity, Th17 and regulatory T cell
biology.
Forward Looking Statement This press release contains statements
that are or may be forward-looking statements, including statements
that relate to the company's future prospects, developments, and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005093/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. Media Tom Donovan +1 857 559 3397
tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De May 2023 a May 2024